Tumor Mutational Burden in Small Cell Lung Cancer: A Valuable Biomarker for Immunotherapy? (BMIC-011) - 102204

Spotlight
Video

Tumor Mutational Burden in Small Cell Lung Cancer: A Valuable Biomarker for Immunotherapy? (BMIC-011)

BeaconMedIC has 21 videos Subscribe Here

Loading........
Description: Dr. Jack West reviews new findings highlighting the utility of using the biomarker tumor mutation burden (TMB) to predict which patients with small cell lung cancer (SCLC) will benefit from nivolumab or the combination of nivolumab with ipilimumab.
Shared By : BeaconMedIC
Posted on : 10/20/17
Added : 3 months ago



More From BeaconMedIC

Nothing found.